Identification of clinically relevant epigenomic events in pediatric acute lymphoblastic leukemia (DFG Research Grant)
Lymphoblastic leukemias are among the most common cancers in children, making up about 30 % of pediatric cancers. Despite advancements in treatment, children with specific genomic alterations like hypoploidy or KMT2A translocations have poor prognoses that are not improved by intensified therapies. These leukemias' molecular mechanisms are poorly understood, particularly regarding epigenomic changes that contribute to disease progression and therapy resistance.
This project aims to fully characterize the epigenomes of BCR/ABL1 and KMT2A-positive leukemias using advanced techniques such as ChIP-Seq, bisulfite sequencing, ATAC-Seq, and RNA-Seq. The findings will enhance our understanding of childhood leukemia's molecular mechanisms and help identify new prognostic markers and therapeutic targets.
Cooperating partners
- Leibniz Institute on Aging – Fritz Lipmann Institute (FLI)
- Hannover Medical School
